Semaglutide — Drug Intelligence | 77 EU Trials

Filter these 77 trials by condition, phase, country and more.

Open in Search →

77 Registered trials

30 Recruiting

30 Completed trials

44 Sponsors

24 Countries

Phase III

Phase II

Phase IV

Phase III: 20 Phase II/III: 1 Phase II: 24 Phase III/IV: 4 Phase IV: 26 Phase I (Other): 1 Other: 1

Oversight events:

7 serious breaches 1 temporary halt across 6 trials

View oversight register →

Indications tested

Obesity 9 Type 2 diabetes mellitus 5 Non-alcoholic steatohepatitis 3 Chronic kidney disease 3 Overweight 3 Diabetes mellitus 2 Acute coronary syndrome 1 Coronary artery disease 1 Multiple sclerosis 1 Palpitations 1 Atrial fibrillation 1 Alcoholic liver disease 1

Sponsors using this IMP

Novo Nordisk A/S 19 Rigshospitalet 5 Region Hovedstaden 4 Region Midtjylland 3 Steno Diabetes Center Copenhagen 3 Aarhus University Hospital 2 Eli Lilly & Co. 2 Karolinska University Hospital 2 Odense University Hospital 2 University College Dublin 2 AstraZeneca AB 1 Azienda Ospedaliero-Universitaria Maggiore Della Carita 1

All trials — page 2

77 total

Effect of Semaglutide on embryo quality in overweight and obese patients undergoing In Vitro Fertilization. A Randomized Controlled Trial Recruiting

2025-522525-34-00 Phase IV 1 country Santiago Dexeus Font Fundacio Privada
SGLT-2i, Heart, Improvement of Cardiovascular Autonomic Neuropathy Recruiting

2025-521748-39-00 Phase IV 1 country Universita Cattolica Del Sacro Cuore
Semaglutide and Finerenone for Kidney and Vascular Protection in CKD Recruiting

2025-522503-18-00 Phase IV 1 country Region Midtjylland
Urinary proteomics to guide early intervention to prevent complications in type 2 diabetes – a feasibility study Recruiting

2024-518682-95-00 Phase IV 2 countries Steno Diabetes Center Copenhagen
A multiarm, randomized, open label Clinical study comparing AntiatheroSClerotic efficacy of selected Antidiabetic agents in patients with co… Recruiting

2023-508525-27-00 Phase IV 1 country Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut …
Searching simple biomarkers to phenotype type 2 diabetic patients and personalize their treatment Recruiting

2024-516542-19-00 Phase IV 1 country Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Exploring GLP-1 Receptor Agonist Treatment for Adolescents with Antipsychotic-Related Obesity: The GOAL Study Recruiting

2024-517471-21-02 Phase IV 1 country Clinical Pharmacology, Department of
CKD-bioMatch: A biomarker-targeted clinical trial to optimize treatment for patients with chronic kidney disease Recruiting

2023-507449-27-01 Phase IV 5 countries Steno Diabetes Center Copenhagen
Sema.Mood Recruiting

2024-511734-13-04 Phase III/IV 1 country Region Hovedstaden
Additive Benefits of Semaglutide for open-AngLe glaucoma – an Opportunity for Neuroprotection (ABSALON) Recruiting

2024-518510-87-00 Phase IV 1 country Rigshospitalet
Semaglutide 2.4mg for low responders after bariatric surgery Recruiting

2022-502164-20-01 Phase IV 1 country Stichting Zuyderland Medisch Centrum
eHealth Based treatment of AdolescenT obesiTy with Low energy diet and sEmaglutide (eBATTLE Obesity) Recruiting

2023-506289-29-00 Phase IV 1 country Vestfold Hospital Trust
An interventional, multi-center, randomized, double blinded, placebo controlled study to investigate semaglutide add-on treatment for metabo… Recruiting

2023-506109-20-00 Phase III 1 country Helse Bergen HF
TOLEDDO: Effect of weekly GLP1 agonist treatment in "double diabetes": a randomized, open-label study Recruiting

2024-514906-30-00 Phase III 1 country Centre Hospitalier Universitaire De Dijon
Semaglutide Treatment for Prevention of Toxicity in High-dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation Recruiting

2022-502139-20-00 Phase II 1 country Rigshospitalet
Safety and efficacy of oral semaglutide in hyperglycaemic patients after renal transplantation Recruiting

2023-504159-29-01 Phase II 1 country Rigshospitalet
New treatments to reduce cardiovascular disease in type 1 diabetes Recruiting

2023-505794-32-04 Phase III 1 country Steno Diabetes Center Copenhagen
The effect of oral Semaglutide on bone turnover in patients with T2D: a randomized placebo-controlled clinical trial (SOBER II) Recruiting

2023-505959-45-00 Phase II 1 country Odense University Hospital
FIT-HF - Effect of weight loss on physical and cardiac performance in patients with heart failure and obesity Recruiting

2023-503753-35-01 Phase II 1 country Region Hovedstaden
Semaglutide for the treatment of glucose intolerance in women with prior gestational diabetes Recruiting

2022-502082-22-00 Phase III/IV 1 country UZ Leuven
Acute Subcutaneous Semaglutide in Acute Ischemic Stroke (ASSET Trial) Recruiting

2022-501072-25-02 Phase II 1 country Aarhus University Hospital
Screening and intervention for subclinical coronary artery disease in patients with type 2 diabetes: THE STENO INTEN-CT STUDY Recruiting

2022-500143-21-01 Phase IV 1 country Aarhus University Hospital; Odense University Hospital
A randomised, controlled, parallel group, open-label trial evaluating the impact of treatment with the GLP-1 analogue semaglutide on weight … Recruiting

2024-513168-24-00 Phase II 3 countries University College Dublin
A Study to Compare Different Doses of RO7795081 with a Placebo or Semaglutide in People with Type 2 Diabetes Ended

2024-520322-11-00 Phase II 3 countries F. Hoffmann-La Roche AG

Showing 25–48 of 77 trials

← All drugs A–Z